Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

TEVA Teva Pharmaceutical Industries Ltd

17,0402

-0,0398 (-0,23%)

22 Nov 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

News Teva Pharmaceutical Industries Ltd

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 21 November 2024 (2 Tage vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 20 November 2024 (3 Tage vor) • Edgar (US Regulatory)

Teva to Present at the Jefferies London Healthcare Conference
Freitag 8 November 2024 (2 Wochen vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 6 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 6 November 2024 (3 Wochen vor) • Edgar (US Regulatory)

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Mittwoch 6 November 2024 (3 Wochen vor) • GlobeNewswire Inc.

U.S. Index Futures Surge on Trump Victory Prospects; Commodities Slide Amid Dollar Strength
Mittwoch 6 November 2024 (3 Wochen vor) • IH Market News

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Freitag 1 November 2024 (3 Wochen vor) • GlobeNewswire Inc.

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as R
Freitag 1 November 2024 (3 Wochen vor) • GlobeNewswire Inc.

Teva Statement on European Commission Decision; Company to Appeal
Donnerstag 31 Oktober 2024 (3 Wochen vor) • GlobeNewswire Inc.

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Dienstag 22 Oktober 2024 (1 Monat vor) • GlobeNewswire Inc.

BP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO Announces Retirement; Berkshire Trims BofA Stake, and More
Freitag 11 Oktober 2024 (1 Monat vor) • IH Market News

Weitere Teva Pharmaceutical Industries Ltd News-Artikel

JP Morgan Chase

Deutsche Telekom

BNP Paribas (QX)

Financial Select Sector

Deutsche Lufthansa

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen